This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Jacobio Pharmaceuticals Group Valuation

Is 1167 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1167 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1167's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1167's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1167?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 1167. This is calculated by dividing 1167's market cap by their current preferred multiple.
What is 1167's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥1.50b

1167 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.1x
Enterprise Value/EBITDA	-0.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 1167's PS Ratio compare to its peers?

The above table shows the PS ratio for 1167 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.3x
2616 CStone Pharmaceuticals	5.4x	34.3%	HK$2.7b
1061 Essex Bio-Technology	0.9x	n/a	HK$1.5b
2137 Brii Biosciences	18x	14.5%	HK$753.1m
2256 Abbisko Cayman	5x	14.2%	HK$2.7b
1167 Jacobio Pharmaceuticals Group	14.7x	-24.8%	HK$1.6b

Price-To-Sales vs Peers: 1167 is good value based on its Price-To-Sales Ratio (14.7x) compared to the peer average (18.3x).

Price to Earnings Ratio vs Industry

How does 1167's PE Ratio compare vs other companies in the HK Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	41.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	41.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 1167 is expensive based on its Price-To-Sales Ratio (14.7x) compared to the Hong Kong Biotechs industry average (10.3x).

Price to Sales Ratio vs Fair Ratio

What is 1167's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1167 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	14.7x
Fair PS Ratio	0.5x

Price-To-Sales vs Fair Ratio: 1167 is expensive based on its Price-To-Sales Ratio (14.7x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.